Pharmaceutical Technology

FEBRUARY 15, 2023

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

Immunity 104

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 104

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The drug candidate is an engineered B-cell modulator.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Business Review

JUNE 19, 2025

CD is said to be a chronic inflammatory condition of the gastrointestinal tract with a complex aetiology involving immune system abnormalities, which may be influenced by genetic, dietary, or environmental factors. Johnson & Johnson’s Janssen Pharmaceutical Companies hold exclusive global marketing rights to the therapy.

Labelling 52

Labelling Immunity Immunization Pharmaceutical Companies 52

pharmaphorum

JANUARY 18, 2021

In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to “one of the largest pharmaceutical companies in the world” based in New Jersey.

Documentation 95

Documentation Immunity Immunization Pharmaceutical Companies 95

European Pharmaceutical Review

AUGUST 9, 2023

The pharmaceutical company announced that it plans to submit to global health authorities in 2024. appeared first on European Pharmaceutical Review. The REMIX data for Novartis’ novel BTK inhibitor will be presented at an upcoming medical meeting. There were 470 participants in the REMIX-1 study.

Immunity 94

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 94

pharmaphorum

FEBRUARY 9, 2022

The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology. A broad front.

Vaccines 134

Vaccines Immunity Immunization Labelling 134

NY Times

APRIL 27, 2021

It feels very American to turn the vaccine rollout into a branding spectacle rooted in the worship of pharmaceutical companies.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Immunization 97

Express Pharma

JUNE 12, 2024

The investigational combination mRNA vaccine generated statistically significant higher immune responses in relation to the licensed comparator vaccines used in the randomised, observer-blind, active control study among 8,000 adults aged 50 years and older. Fluzone high-dose and Fluarix for influenza, and Spikevax for Covid-19.

Vaccines 104

Vaccines Adverse Reactions Immunity Immunization 104

European Pharmaceutical Review

SEPTEMBER 21, 2023

IL-13 has a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms. The monoclonal antibody biologic treatment has been developed to bind to and inhibit the interleukin (IL)-13 cytokine. It inhibits interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).

Immunization 105

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

FEBRUARY 14, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. AC Immune and F. Hoffmann-La Roche are the other key patent filers in neuro-degenerative receptor binding drug compositions.

Biosimilars 98

Biosimilars Immunization Immunity Pharmaceutical Companies 98

Express Pharma

MAY 27, 2025

Datroway is currently being evaluated in five Phase III clinical trials as a first-line therapy in combination with immune checkpoint inhibitors (ICIs), bispecific antibodies, and epidermal growth factor receptor inhibitors. AbbVie, AstraZeneca, and Daiichi Sankyo.

Chemotherapy 76

Chemotherapy Immunization Immunity Pharmaceutical Companies 76

Pharmaceutical Technology

SEPTEMBER 14, 2022

Most drugs available for the treatment of UC weaken patients’ immune systems, which puts them at higher risk of infection. Key opinion leaders (KOLs) interviewed by GlobalData have suggested that this group of patients would benefit from a greater number of treatment options that cause less systemic immune-related side effects.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

APRIL 17, 2023

Australian pharmaceutical company Incannex has appointed Quest Pharmaceutical Services (QPS) to advance CannQuit-N (Nicotine), CannQuit-O (Opioid) and Renecann Products in the USA and the European Union (EU). French company Eurofins Scientific is currently developing and manufacturing both products.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Business Review

AUGUST 28, 2024

A fully human monoclonal antibody, Libtayo acts on the immune checkpoint receptor PD-1 on T cells. The company’s footprint spans 16 markets and employs over 12,000 individuals. It is said to be the first-line monotherapy approved for advanced non-small cell lung cancer (NSCLC).

Immunity 59

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 59

NY Times

JANUARY 7, 2021

Readers discuss an Op-Ed that argued that pharmaceutical companies don’t deserve the public relations lift from the rapid vaccine development.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Immunization 59

Pharmaceutical Technology

MARCH 9, 2023

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Immunity 59

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

SEPTEMBER 22, 2021

Some pharmaceutical companies, including Chiesi, established emergency committees to build business continuity plans and contingencies to protect drug supply and worker safety. Despite COVID-19, we expanded the new business unit to 275 employees in more than 20 countries in just 18 months.

Immunity 111

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 111

pharmaphorum

OCTOBER 21, 2022

Mukherjee explained that the human immune system becomes weaker as people age, which leads to a greater susceptibility to catching infectious diseases and also experiencing more acute cases when infected.

Vaccines 98

Vaccines Immunity Immunization Compounding 98

pharmaphorum

JUNE 8, 2021

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

pharmaphorum

JANUARY 31, 2022

The digital transformation is allowing pharmaceutical companies to expand their drug discovery capabilities and accelerate drug development. As Shanaya says, some of the biggest developments have involved mRNA vaccines, “a completely different way to stimulate an immune response.”. Innovation at Pfizer.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

The Thyroid Pharmacist

NOVEMBER 29, 2023

The truth is that most supplement companies do not undergo the same scrutiny and testing that pharmaceutical products do, because many of the tests which are required of pharmaceutical companies are voluntary for supplement companies. We have 290 expiring in April 2025.)

Health and Personal Care Stores 81

Health and Personal Care Stores Immunization Immunity Labelling 81

Pharmaceutical Technology

FEBRUARY 26, 2023

Cue Biopharma overview Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 26, 2023

Cue Biopharma overview Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

MARCH 10, 2022

Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases. Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 98

Pharmaceutical Technology

MARCH 1, 2023

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Immunization 40

Pharmaceutical Technology

MARCH 1, 2023

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Immunization 40

pharmaphorum

SEPTEMBER 20, 2022

The two companies have been talking to each other since 2017 and formally working together since 2019, when Pfizer started using CytoReason’s biological models in research aimed at developing new drugs for immune-mediated diseases and cancer immunotherapies.

Drug Development 52

Drug Development Immunization Immunity Pharmaceutical Companies 52

European Pharmaceutical Review

AUGUST 14, 2023

Swedish pharmaceutical company Vicore Pharma is developing treatments for diseases where the angiotensin II type 2 receptor (AT2R) has a central role in stopping and reversing disease pathology and where there is a large unmet medical need. The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG).

Labelling 98

Labelling Immunity Immunization Pharmaceutical Companies 98

pharmaphorum

OCTOBER 16, 2020

Now, as part of lifecycle management, pharmaceutical companies are looking more closely at drugs they have on their shelves. In 2020, the pharmaceutical industry has not by any means proved immune to the disruption caused by COVID-19.

Drug Development 105

Drug Development Immunity Immunization Pharmaceutical Companies 105

Pharmaceutical Technology

MAY 8, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Hoffmann-La Roche is a biotechnology company that develops drugs and diagnostics to treat major diseases.

Mayo Clinic 52

Mayo Clinic Immunization Immunity Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Historically, federal funding has been used to develop vaccines, as infectious disease markets are often not as lucrative as other indications.

52

52

Pharmaceutical Technology

FEBRUARY 15, 2023

The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response.

Vaccines 52

Vaccines Immunization Immunity Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 24, 2023

Eli Lilly and Co Overview Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly is headquartered in Indianapolis, Indiana, the US.

Diabetes 45

Diabetes Immunization Immunity Pharmaceutical Companies 45

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Coronavirus vaccine components is a key innovation area in pharmaceuticals Components used in vaccines include antigens, preservatives, stabilisers, surfactants, residuals, diluents, and adjuvants. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccines 52

Vaccines Immunity Immunization Pharmaceutical Companies 52

Digital Pharmacist

OCTOBER 24, 2022

When it comes to innovation in the development of new drugs and therapeutic biological products in the pharmaceutical industry, the United States Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) is a key supporter of the pharmaceutical industry. .

Adverse Reactions 75

Adverse Reactions Labelling Pharmacy Management Immunity 75

pharmaphorum

MAY 18, 2022

To stem these demands, complement internal pipelines with promising external science and create differentiated value for patients, a lot of pharmaceutical companies are currently looking for strategic collaborations and acquisitions. With more than 8,000 people in approximately 40 countries, the company generated revenue of €5.8

Immunity 92

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 92

European Pharmaceutical Review

MARCH 7, 2024

Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunity Immunization 52